News and Updates

Breakthrough T1D funded 3 projects to address eating disorders + T1D and a study that presents the risks of T1D eating disorders and current barriers to safe treatment.

In 2023 alone, there have been several important papers published on disease-modifying therapies (DMT) for type 1 diabetes. This blog explains everything you need to know about several DMTs.

Breakthrough T1D and ISAPD announce the recipients of the 2023 fellowships. These fellowships will help bring the best in T1D care to new communities around the world.

A guest post from Breakthrough T1D's social media manager, Grace Bennett, about life-with-T1D lessons she's learned in 19+ years.

In a Breakthrough T1D-funded clinical trial and published in the New England Journal of Medicine, baricitinib preserved beta cell function in type 1 diabetes.

Leading diabetes researchers gathered for the annual ISPAD conference. More than 45 studies were presented by Breakthrough T1D researchers, including Tzield.

A new study published in the New England Journal of Medicine shows Tzield can preserve beta cell health in certain individuals recently diagnosed with T1D.

We take a closer look at what insulin resistance is, the risks associated with it for people with type 1 diabetes, and the latest research to address it.

Leading researchers from around the world will gather for the ISPAD annual conference, with more than 45 studies presented by Breakthrough T1D-funded researchers.

Leading researchers gathered for the annual meeting of the European Association for the Study of Diabetes (EASD), which took place from October 2-6.